Markets:

Overview

News

Currencies

International

Treasuries

MindWalk Holdings Corp. - Common Stock (NQ:HYFT)

1.370 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about MindWalk Holdings Corp. - Common Stock

< Previous 1 2 Next >

AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test

October 14, 2026

From Biotech Insider

Via GlobeNewswire

MindWalk Holdings Corp. Strengthens Boston-Based Development Leadership as Pipeline Advances Toward Preclinical Efficacy Studies

October 14, 2026

From MindWalk Holdings Corp.

Via Business Wire

Drug Discovery Informatics Market Projected to Reach $7.74 Billion by 2030 as AI Agents Need Biological Context

October 06, 2026

From Equity Insider

Via GlobeNewswire

MindWalk (NASDAQ: HYFT): Enterprise AI Has Found Its Ontology Layer. Biology Needs One Grounded in Biological Function

October 06, 2026

From MindWalk Holdings Corp.

Via Business Wire

MindWalk Appoints Kim Remizowski to Board of Directors as Independent Director

October 01, 2026

From MindWalk Holdings Corp.

Via Business Wire

Chipmakers Now Ship Protein-Folding AI as Plug-and-Play Microservices

September 22, 2026

News Provided by American News Group on behalf of MindWalk Holdings Corp.

From American News Group

Via GlobeNewswire

MindWalk Brings OpenFold3 into Production in Minutes with AMD Inference Microservices on Vultr Kubernetes Engine

September 21, 2026

From MindWalk Holdings Corp.

Via Business Wire

MindWalk Reports 21% Revenue Growth and Gross Margin Expansion to 59% in Fiscal First Quarter 2027

September 14, 2026

From MindWalk Holdings Corp.

Via Business Wire

MindWalk Lands Binding Commitment for US$30 Million Unsecured Credit Facility to Fund Biologics Programs and Commercial Expansion

September 14, 2026

From MindWalk Holdings Corp.

Via Business Wire

MindWalk to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 10, 2026

From MindWalk Holdings Corp.

Via Business Wire

MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2027 on September 14, 2026

September 08, 2026

From MindWalk Holdings Corp.

Via Business Wire

The Market Just Told You Which Layer Of AI Biology It Is Paying For

September 03, 2026

Issued on behalf of MindWalk Holdings Corp.

From Market Updates

Via GlobeNewswire

Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.

August 19, 2026

News Provided by USA News Group on behalf of MindWalk Holdings Corp.

From USA News Group

Via GlobeNewswire

AI Found an Influenza Target That Survives Viral Mutation

August 10, 2026

Issued on behalf of MindWalk Holdings Corp. (Nasdaq: HYFT)

From Equity Insider

Via GlobeNewswire

MindWalk Showcases ReefIQ™ for AI Drug Discovery at AMD Advancing AI

July 23, 2026

From MindWalk Holdings Corp.

Via Business Wire

MindWalk Holdings Corp. Reports Fiscal 2026 Results: Revenue Up 46% as the Company Completes Its Pivot to Bio-Native AI Infrastructure

July 22, 2026

From MindWalk Holdings Corp.

Via Business Wire

MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2026 on July 22, 2026

July 13, 2026

From MindWalk Holdings Corp.

Via Business Wire

MindWalk Holdings Corp. (NASDAQ: HYFT) Added to the Russell 3000E Index, Expanding Institutional Investment Opportunity

July 06, 2026

From MindWalk Holdings Corp.

Via Business Wire

MindWalk (NASDAQ: HYFT) Files Patent for High-Dimensional Biological Data Architecture Powering AI Drug Discovery

July 01, 2026

From MindWalk Holdings Corp.

Via Business Wire

MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discovery

June 12, 2026

From MindWalk Holdings Corp.

Via Business Wire

MindWalk Holdings Corp. (NASDAQ: HYFT) Launches ReefIQ™, a Biological Context Layer for AI Drug Discovery

June 10, 2026

From MindWalk Holdings Corp.

Via Business Wire

MindWalk's Preclinical Dengue Data Support a HYFT® Computational Prediction: Immunogens Designed on the Predicted Target Elicited Cross-Reactive Antibodies Against Antigens of All Four Dengue Serotypes, Reproduced Across Two Independent Campaigns

June 02, 2026

From MindWalk Holdings Corp.

Via Business Wire

MindWalk Holdings Deploys Pandemic Response Platform via HYFT® Technology as Ebola and Hantavirus Outbreaks Expose the Limits of Strain-Specific Coverage

May 27, 2026

From MindWalk Holdings Corp.

Via Business Wire

The Biology Came First.

May 18, 2026

From MindWalk Holdings Corp.

Via Business Wire

MindWalk Holdings Corp. Reports Q3 Fiscal 2026 Financial Results

March 12, 2026

From MindWalk Holdings Corp.

Via Business Wire

MindWalk Announces B Cell Llama™, a Nanobody Discovery Platform Designed for the Bispecific and Cell Therapy Era

March 06, 2026

From MindWalk Holdings Corp.

Via Business Wire

MindWalk Holdings Corp. to Report Third Quarter Fiscal Year 2026 Financial Results on March 12, 2026

March 02, 2026

From MindWalk Holdings Corp.

Via Business Wire

MindWalk Applies HYFT® Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics

January 27, 2026

From MindWalk Holdings Corp.

Via Business Wire

MindWalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic TDP-43 in Neurodegenerative Disease

January 14, 2026

From MindWalk Holdings Corp.

Via Business Wire

REPEAT/MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight

January 12, 2026

From MindWalk Holdings Corp.

Via Business Wire

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.